Zymeworks Announces Participation in Upcoming Investor Conference
May 27 2022 - 5:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing next-generation multifunctional biotherapeutics,
today announced that management will participate in an upcoming
investor conference:
- Jefferies Healthcare Conference. Zymeworks will
participate in one-on-one meetings on June 8th – 9th and will
present on June 8th at 9:30 a.m. ET in New York, NY.
The presentation will be available on Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc. Zymeworks is a clinical-stage
biopharmaceutical company dedicated to the discovery, development
and commercialization of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, zanidatamab, is a novel Azymetric™
HER2-targeted bispecific antibody currently being evaluated in
multiple Phase 1, Phase 2, and pivotal clinical trials globally as
a targeted treatment option for patients with solid tumors that
express HER2. Zymeworks’ second clinical candidate, ZW49, is a
novel bispecific HER2‑targeted antibody-drug conjugate currently in
Phase 1 clinical development and combines the unique design and
antibody framework of zanidatamab with Zymeworks’ proprietary
ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with global
biopharmaceutical companies. For more information on our ongoing
clinical trials visit www.zymeworksclinicaltrials.com. For
additional information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220527005050/en/
Investor Inquiries: Jack Spinks (604) 678-1388
ir@zymeworks.com
Media Inquiries: Diana Papove (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024